SpinalCyte was issued Canadian Patent No. 2,641,170, “Methods and Compositions for Repair of Cartilage using an In Vivo Bioreactor."
The technology, which supports tissue engineering, incorporates a synthetic polymer matrix, a natural hydrogel or a synthetic hydrogel to expose fibroblasts to a mechanical strain using intermittent hydrostatic pressure or fluid shear stress. Other claims provide for growth factors such as bone morphogenetic proteins 2, 4, 6 and 7, transforming growth factor and insulin growth factor.
Source: SpinalCyte, LLC
This adds to SpinalCyte's issued patents in Australia, Japan and the U.S.
In 2014, the company entered a final animal trial with its spinal nucleus replacement technology based on human dermal fibroblasts. Initial animal trials succeeded in regrowing the nucleus and restoring disc height by >80%.